ID   SERA_HUMAN              Reviewed;         533 AA.
AC   O43175; B2RD08; Q5SZU3; Q9BQ01;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=D-3-phosphoglycerate dehydrogenase;
DE            Short=3-PGDH;
DE            EC=1.1.1.95 {ECO:0000269|PubMed:11751922};
DE   AltName: Full=2-oxoglutarate reductase {ECO:0000305};
DE            EC=1.1.1.399 {ECO:0000269|PubMed:25406093};
DE   AltName: Full=Malate dehydrogenase {ECO:0000305};
DE            EC=1.1.1.37 {ECO:0000269|PubMed:25406093};
GN   Name=PHGDH; Synonyms=PGDH3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10713460; DOI=10.1016/S0378-1119(00)00009-3;
RA   Cho H.M., Jun D.Y., Bae M.A., Ahn J.D., Kim Y.H.;
RT   "Nucleotide sequence and differential expression of the human 3-
RT   phosphoglycerate dehydrogenase gene.";
RL   Gene 245:193-201(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS PHGDHD MET-425 AND MET-490.
RX   PubMed=11055895; DOI=10.1086/316886;
RA   Klomp L.W.J., de Koning T.J., Malingre H.E.M., van Beurden E.A.C.M.,
RA   Brink M., Opdam F.L., Duran M., Jaeken J., Pineda M.,
RA   van Maldergem L., Poll-The B.T., van den Berg I.E.T., Berger R.;
RT   "Molecular characterization of 3-phosphoglycerate dehydrogenase
RT   deficiency -- a neurometabolic disorder associated with reduced L-
RT   serine biosynthesis.";
RL   Am. J. Hum. Genet. 67:1389-1399(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-54; 59-69; 76-119; 138-155; 237-289; 295-308;
RP   352-380; 385-394; 462-491 AND 523-533, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma, and Ovarian carcinoma;
RA   Bienvenut W.V.;
RL   Submitted (JAN-2010) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 9-20; 22-33; 76-90; 248-268 AND 271-289.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   CATALYTIC ACTIVITY, AND VARIANT MET-490.
RX   PubMed=11751922; DOI=10.1074/jbc.M111419200;
RA   Pind S., Slominski E., Mauthe J., Pearlman K., Swoboda K.J.,
RA   Wilkins J.A., Sauder P., Natowicz M.R.;
RT   "V490M, a common mutation in 3-phosphoglycerate dehydrogenase
RT   deficiency, causes enzyme deficiency by decreasing the yield of mature
RT   enzyme.";
RL   J. Biol. Chem. 277:7136-7143(2002).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND INDUCTION BY
RP   17-BETA-ESTRADIOL AND 4-HYDROXYTAMOXIFEN.
RX   PubMed=16949628; DOI=10.1016/j.steroids.2006.07.006;
RA   Al-Dhaheri M.H., Shah Y.M., Basrur V., Pind S., Rowan B.G.;
RT   "Identification of novel proteins induced by estradiol, 4-
RT   hydroxytamoxifen and acolbifene in T47D breast cancer cells.";
RL   Steroids 71:966-978(2006).
RN   [12]
RP   INDUCTION BY SP1 AND NF-Y.
RX   PubMed=18378410; DOI=10.1016/j.gene.2008.02.018;
RA   Jun D.Y., Park H.S., Lee J.Y., Baek J.Y., Park H.-K., Fukui K.,
RA   Kim Y.H.;
RT   "Positive regulation of promoter activity of human 3-phosphoglycerate
RT   dehydrogenase (PHGDH) gene is mediated by transcription factors Sp1
RT   and NF-Y.";
RL   Gene 414:106-114(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-78, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND THR-78, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-21, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [18]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=25406093; DOI=10.1021/cb500683c;
RA   Fan J., Teng X., Liu L., Mattaini K.R., Looper R.E.,
RA   Vander Heiden M.G., Rabinowitz J.D.;
RT   "Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-
RT   hydroxyglutarate.";
RL   ACS Chem. Biol. 10:510-516(2015).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 4-314 IN COMPLEX WITH NAD AND
RP   SUBSTRATE.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human 3-phosphoglycerate dehydrogenase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [21]
RP   VARIANTS PHGDHD TRP-135; MET-261; THR-373 AND SER-377,
RP   CHARACTERIZATION OF VARIANTS PHGDHD TRP-135; MET-261; THR-373;
RP   SER-377; MET-425 AND MET-490, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19235232; DOI=10.1002/humu.20934;
RA   Tabatabaie L., de Koning T.J., Geboers A.J.J.M., van den Berg I.E.T.,
RA   Berger R., Klomp L.W.J.;
RT   "Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are
RT   distributed throughout the protein and result in altered enzyme
RT   kinetics.";
RL   Hum. Mutat. 30:749-756(2009).
RN   [22]
RP   INVOLVEMENT IN NLS1, AND VARIANTS NLS1 ARG-140 AND GLN-163.
RX   PubMed=24836451; DOI=10.1016/j.ajhg.2014.04.015;
RA   Shaheen R., Rahbeeni Z., Alhashem A., Faqeih E., Zhao Q., Xiong Y.,
RA   Almoisheer A., Al-Qattan S.M., Almadani H.A., Al-Onazi N.,
RA   Al-Baqawi B.S., Saleh M.A., Alkuraya F.S.;
RT   "Neu-Laxova syndrome, an inborn error of serine metabolism, is caused
RT   by mutations in PHGDH.";
RL   Am. J. Hum. Genet. 94:898-904(2014).
CC   -!- FUNCTION: Catalyzes the reversible oxidation of 3-phospho-D-
CC       glycerate to 3-phosphonooxypyruvate, the first step of the
CC       phosphorylated L-serine biosynthesis pathway. Also catalyzes the
CC       reversible oxidation of 2-hydroxyglutarate to 2-oxoglutarate and
CC       the reversible oxidation of (S)-malate to oxaloacetate.
CC       {ECO:0000269|PubMed:11751922, ECO:0000269|PubMed:25406093}.
CC   -!- CATALYTIC ACTIVITY: 3-phospho-D-glycerate + NAD(+) = 3-
CC       phosphonooxypyruvate + NADH. {ECO:0000269|PubMed:11751922}.
CC   -!- CATALYTIC ACTIVITY: (R)-2-hydroxyglutarate + NAD(+) = 2-
CC       oxoglutarate + NADH. {ECO:0000269|PubMed:25406093}.
CC   -!- CATALYTIC ACTIVITY: (S)-malate + NAD(+) = oxaloacetate + NADH.
CC       {ECO:0000269|PubMed:25406093}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=21.6 uM for 3-phosphonooxypyruvate
CC         {ECO:0000269|PubMed:19235232};
CC         KM=0.26 mM for 3-phosphoglycerate {ECO:0000269|PubMed:25406093};
CC         KM=6.5 mM for oxaloacetate {ECO:0000269|PubMed:25406093};
CC         KM=10.1 mM for 2-oxoglutarate {ECO:0000269|PubMed:25406093};
CC         KM=22 uM for NAD(+) {ECO:0000269|PubMed:25406093};
CC         KM=4 uM for NADH {ECO:0000269|PubMed:25406093};
CC         Vmax=35 nmol/min/mg enzyme with 3-phosphohydroxypyruvate as
CC         substrate (in patient-derived fibroblasts)
CC         {ECO:0000269|PubMed:19235232};
CC         Vmax=168 nmol/min/mg enzyme with 3-phosphohydroxypyruvate as
CC         substrate (in 3-PGDH overexpressed cells)
CC         {ECO:0000269|PubMed:19235232};
CC         Note=kcat is 4.5 min(-1) for 3-phosphoglycerate oxidation. kcat
CC         is 10.6 min(-1) for oxaloacetate reduction. kcat is 4.7 min(-1)
CC         for 2-oxoglutarate reduction. {ECO:0000269|PubMed:25406093};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-serine biosynthesis; L-serine
CC       from 3-phospho-D-glycerate: step 1/3.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000250|UniProtKB:O08651}.
CC   -!- INDUCTION: Induced by 17-beta-estradiol (estrogenic ligand) and 4-
CC       hydroxytamoxifen (agonist/antagonist ligand). Positively regulated
CC       by the transcription factors SP1 and NF-Y.
CC       {ECO:0000269|PubMed:16949628, ECO:0000269|PubMed:18378410}.
CC   -!- DISEASE: Phosphoglycerate dehydrogenase deficiency (PHGDHD)
CC       [MIM:601815]: An autosomal recessive inborn error of L-serine
CC       biosynthesis, clinically characterized by congenital microcephaly,
CC       psychomotor retardation, and seizures.
CC       {ECO:0000269|PubMed:11055895, ECO:0000269|PubMed:19235232}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Neu-Laxova syndrome 1 (NLS1) [MIM:256520]: A lethal,
CC       autosomal recessive multiple malformation syndrome characterized
CC       by ichthyosis, marked intrauterine growth restriction,
CC       microcephaly, short neck, limb deformities, hypoplastic lungs,
CC       edema, and central nervous system anomalies including
CC       lissencephaly, cerebellar hypoplasia and/or abnormal/agenesis of
CC       the corpus callosum. Abnormal facial features include severe
CC       proptosis with ectropion, hypertelorism, micrognathia, flattened
CC       nose, and malformed ears. {ECO:0000269|PubMed:24836451}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the D-isomer specific 2-hydroxyacid
CC       dehydrogenase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF006043; AAB88664.1; -; mRNA.
DR   EMBL; AF171237; AAD51415.1; -; mRNA.
DR   EMBL; CR456795; CAG33076.1; -; mRNA.
DR   EMBL; AK315360; BAG37755.1; -; mRNA.
DR   EMBL; AL589734; CAI22407.1; -; Genomic_DNA.
DR   EMBL; AL139251; CAI22407.1; JOINED; Genomic_DNA.
DR   EMBL; AL139251; CAI22212.1; -; Genomic_DNA.
DR   EMBL; AL589734; CAI22212.1; JOINED; Genomic_DNA.
DR   EMBL; CH471122; EAW56708.1; -; Genomic_DNA.
DR   EMBL; BC000303; AAH00303.1; -; mRNA.
DR   EMBL; BC001349; AAH01349.1; -; mRNA.
DR   EMBL; BC011262; AAH11262.1; -; mRNA.
DR   CCDS; CCDS904.1; -.
DR   RefSeq; NP_006614.2; NM_006623.3.
DR   UniGene; Hs.487296; -.
DR   PDB; 2G76; X-ray; 1.70 A; A/B=4-315.
DR   PDBsum; 2G76; -.
DR   ProteinModelPortal; O43175; -.
DR   SMR; O43175; -.
DR   BioGrid; 117618; 117.
DR   IntAct; O43175; 40.
DR   MINT; MINT-4999739; -.
DR   STRING; 9606.ENSP00000358417; -.
DR   BindingDB; O43175; -.
DR   ChEMBL; CHEMBL2311243; -.
DR   DrugBank; DB00157; NADH.
DR   iPTMnet; O43175; -.
DR   PhosphoSitePlus; O43175; -.
DR   SwissPalm; O43175; -.
DR   BioMuta; PHGDH; -.
DR   EPD; O43175; -.
DR   MaxQB; O43175; -.
DR   PaxDb; O43175; -.
DR   PeptideAtlas; O43175; -.
DR   PRIDE; O43175; -.
DR   TopDownProteomics; O43175; -.
DR   DNASU; 26227; -.
DR   Ensembl; ENST00000369409; ENSP00000358417; ENSG00000092621.
DR   GeneID; 26227; -.
DR   KEGG; hsa:26227; -.
DR   UCSC; uc001ehz.4; human.
DR   CTD; 26227; -.
DR   DisGeNET; 26227; -.
DR   GeneCards; PHGDH; -.
DR   HGNC; HGNC:8923; PHGDH.
DR   HPA; CAB003681; -.
DR   HPA; CAB068216; -.
DR   HPA; HPA021241; -.
DR   HPA; HPA024031; -.
DR   MalaCards; PHGDH; -.
DR   MIM; 256520; phenotype.
DR   MIM; 601815; phenotype.
DR   MIM; 606879; gene.
DR   neXtProt; NX_O43175; -.
DR   OpenTargets; ENSG00000092621; -.
DR   Orphanet; 79351; 3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form.
DR   Orphanet; 2671; Neu-Laxova syndrome.
DR   PharmGKB; PA33264; -.
DR   eggNOG; KOG0068; Eukaryota.
DR   eggNOG; COG0111; LUCA.
DR   GeneTree; ENSGT00840000129939; -.
DR   HOGENOM; HOG000136693; -.
DR   HOVERGEN; HBG054241; -.
DR   InParanoid; O43175; -.
DR   KO; K00058; -.
DR   OMA; DNTFAQC; -.
DR   OrthoDB; EOG091G0C5D; -.
DR   PhylomeDB; O43175; -.
DR   TreeFam; TF314548; -.
DR   BioCyc; MetaCyc:HS01776-MONOMER; -.
DR   BRENDA; 1.1.1.95; 2681.
DR   Reactome; R-HSA-977347; Serine biosynthesis.
DR   UniPathway; UPA00135; UER00196.
DR   ChiTaRS; PHGDH; human.
DR   EvolutionaryTrace; O43175; -.
DR   GeneWiki; Phosphoglycerate_dehydrogenase; -.
DR   GenomeRNAi; 26227; -.
DR   PRO; PR:O43175; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000092621; -.
DR   CleanEx; HS_PHGDH; -.
DR   ExpressionAtlas; O43175; baseline and differential.
DR   Genevisible; O43175; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0009055; F:electron carrier activity; TAS:UniProtKB.
DR   GO; GO:0030060; F:L-malate dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0004617; F:phosphoglycerate dehydrogenase activity; TAS:Reactome.
DR   GO; GO:0007420; P:brain development; TAS:ProtInc.
DR   GO; GO:0070314; P:G1 to G0 transition; IEA:Ensembl.
DR   GO; GO:0009448; P:gamma-aminobutyric acid metabolic process; IEA:Ensembl.
DR   GO; GO:0021782; P:glial cell development; IEA:Ensembl.
DR   GO; GO:0006541; P:glutamine metabolic process; IEA:Ensembl.
DR   GO; GO:0006544; P:glycine metabolic process; IEA:Ensembl.
DR   GO; GO:0006564; P:L-serine biosynthetic process; TAS:Reactome.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0021510; P:spinal cord development; IEA:Ensembl.
DR   GO; GO:0019530; P:taurine metabolic process; IEA:Ensembl.
DR   GO; GO:0006566; P:threonine metabolic process; IEA:Ensembl.
DR   Gene3D; 3.30.1330.90; -; 1.
DR   InterPro; IPR029009; ASB_dom.
DR   InterPro; IPR006139; D-isomer_2_OHA_DH_cat_dom.
DR   InterPro; IPR029753; D-isomer_DH_CS.
DR   InterPro; IPR029752; D-isomer_DH_CS1.
DR   InterPro; IPR006140; D-isomer_DH_NAD-bd.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR006236; PGDH.
DR   Pfam; PF00389; 2-Hacid_dh; 1.
DR   Pfam; PF02826; 2-Hacid_dh_C; 1.
DR   SUPFAM; SSF143548; SSF143548; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR01327; PGDH; 1.
DR   PROSITE; PS00065; D_2_HYDROXYACID_DH_1; 1.
DR   PROSITE; PS00670; D_2_HYDROXYACID_DH_2; 1.
DR   PROSITE; PS00671; D_2_HYDROXYACID_DH_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Amino-acid biosynthesis; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Isopeptide bond; NAD;
KW   Oxidoreductase; Phosphoprotein; Reference proteome;
KW   Serine biosynthesis; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|Ref.8}.
FT   CHAIN         2    533       D-3-phosphoglycerate dehydrogenase.
FT                                /FTId=PRO_0000076012.
FT   NP_BIND     155    156       NAD. {ECO:0000269|Ref.20}.
FT   NP_BIND     234    236       NAD. {ECO:0000269|Ref.20}.
FT   NP_BIND     283    286       NAD. {ECO:0000269|Ref.20}.
FT   ACT_SITE    236    236
FT   ACT_SITE    265    265       {ECO:0000250}.
FT   ACT_SITE    283    283       Proton donor.
FT   BINDING      78     78       NAD. {ECO:0000269|Ref.20}.
FT   BINDING     175    175       NAD. {ECO:0000269|Ref.20}.
FT   BINDING     207    207       NAD; via carbonyl oxygen.
FT                                {ECO:0000269|Ref.20}.
FT   BINDING     260    260       NAD. {ECO:0000269|Ref.20}.
FT   MOD_RES       2      2       N-acetylalanine. {ECO:0000269|Ref.8}.
FT   MOD_RES      14     14       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      21     21       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61753}.
FT   MOD_RES      58     58       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q61753}.
FT   MOD_RES      78     78       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   CROSSLNK     21     21       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK     21     21       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   VARIANT     135    135       R -> W (in PHGDHD; results in a 2-fold
FT                                decrease in enzyme activity with 3-
FT                                phosphohydroxypyruvate, but no change in
FT                                substrate affinity; dbSNP:rs267606949).
FT                                {ECO:0000269|PubMed:19235232}.
FT                                /FTId=VAR_059026.
FT   VARIANT     140    140       G -> R (in NLS1; dbSNP:rs587777770).
FT                                {ECO:0000269|PubMed:24836451}.
FT                                /FTId=VAR_071819.
FT   VARIANT     163    163       R -> Q (in NLS1; dbSNP:rs587777483).
FT                                {ECO:0000269|PubMed:24836451}.
FT                                /FTId=VAR_071820.
FT   VARIANT     261    261       V -> M (in PHGDHD; results in a four-fold
FT                                decrease in substrate affinity and a
FT                                slight increase in maximal enzyme
FT                                activity with 3-phosphohydroxypyruvate;
FT                                dbSNP:rs267606947).
FT                                {ECO:0000269|PubMed:19235232}.
FT                                /FTId=VAR_059027.
FT   VARIANT     373    373       A -> T (in PHGDHD; results in almost
FT                                undetectable enzyme activity with 3-
FT                                phosphohydroxypyruvate).
FT                                {ECO:0000269|PubMed:19235232}.
FT                                /FTId=VAR_059028.
FT   VARIANT     377    377       G -> S (in PHGDHD; results in a 2-fold
FT                                decrease in enzyme activity with 3-
FT                                phosphohydroxypyruvate, but no change in
FT                                substrate affinity; dbSNP:rs267606948).
FT                                {ECO:0000269|PubMed:19235232}.
FT                                /FTId=VAR_059029.
FT   VARIANT     425    425       V -> M (in PHGDHD; results in almost
FT                                undetectable enzyme activity with 3-
FT                                phosphohydroxypyruvate;
FT                                dbSNP:rs121907988).
FT                                {ECO:0000269|PubMed:11055895,
FT                                ECO:0000269|PubMed:19235232}.
FT                                /FTId=VAR_013461.
FT   VARIANT     490    490       V -> M (in PHGDHD; results in almost
FT                                undetectable enzyme activity with 3-
FT                                phosphohydroxypyruvate;
FT                                dbSNP:rs121907987).
FT                                {ECO:0000269|PubMed:11055895,
FT                                ECO:0000269|PubMed:11751922,
FT                                ECO:0000269|PubMed:19235232}.
FT                                /FTId=VAR_059030.
FT   CONFLICT     25     25       D -> E (in Ref. 1; AAB88664/AAD51415).
FT                                {ECO:0000305}.
FT   STRAND        8     11       {ECO:0000244|PDB:2G76}.
FT   HELIX        18     26       {ECO:0000244|PDB:2G76}.
FT   STRAND       29     32       {ECO:0000244|PDB:2G76}.
FT   HELIX        38     44       {ECO:0000244|PDB:2G76}.
FT   HELIX        45     47       {ECO:0000244|PDB:2G76}.
FT   STRAND       49     53       {ECO:0000244|PDB:2G76}.
FT   STRAND       55     57       {ECO:0000244|PDB:2G76}.
FT   HELIX        61     66       {ECO:0000244|PDB:2G76}.
FT   STRAND       72     79       {ECO:0000244|PDB:2G76}.
FT   HELIX        85     91       {ECO:0000244|PDB:2G76}.
FT   STRAND       94     96       {ECO:0000244|PDB:2G76}.
FT   HELIX       103    119       {ECO:0000244|PDB:2G76}.
FT   HELIX       121    129       {ECO:0000244|PDB:2G76}.
FT   HELIX       136    138       {ECO:0000244|PDB:2G76}.
FT   STRAND      147    151       {ECO:0000244|PDB:2G76}.
FT   HELIX       155    165       {ECO:0000244|PDB:2G76}.
FT   TURN        166    168       {ECO:0000244|PDB:2G76}.
FT   STRAND      170    174       {ECO:0000244|PDB:2G76}.
FT   STRAND      176    178       {ECO:0000244|PDB:2G76}.
FT   HELIX       180    185       {ECO:0000244|PDB:2G76}.
FT   HELIX       193    196       {ECO:0000244|PDB:2G76}.
FT   HELIX       197    199       {ECO:0000244|PDB:2G76}.
FT   STRAND      201    205       {ECO:0000244|PDB:2G76}.
FT   TURN        211    215       {ECO:0000244|PDB:2G76}.
FT   HELIX       219    222       {ECO:0000244|PDB:2G76}.
FT   STRAND      229    233       {ECO:0000244|PDB:2G76}.
FT   HELIX       242    251       {ECO:0000244|PDB:2G76}.
FT   STRAND      252    260       {ECO:0000244|PDB:2G76}.
FT   STRAND      263    266       {ECO:0000244|PDB:2G76}.
FT   HELIX       271    274       {ECO:0000244|PDB:2G76}.
FT   STRAND      278    280       {ECO:0000244|PDB:2G76}.
FT   HELIX       289    306       {ECO:0000244|PDB:2G76}.
SQ   SEQUENCE   533 AA;  56651 MW;  C58EB72275C45B35 CRC64;
     MAFANLRKVL ISDSLDPCCR KILQDGGLQV VEKQNLSKEE LIAELQDCEG LIVRSATKVT
     ADVINAAEKL QVVGRAGTGV DNVDLEAATR KGILVMNTPN GNSLSAAELT CGMIMCLARQ
     IPQATASMKD GKWERKKFMG TELNGKTLGI LGLGRIGREV ATRMQSFGMK TIGYDPIISP
     EVSASFGVQQ LPLEEIWPLC DFITVHTPLL PSTTGLLNDN TFAQCKKGVR VVNCARGGIV
     DEGALLRALQ SGQCAGAALD VFTEEPPRDR ALVDHENVIS CPHLGASTKE AQSRCGEEIA
     VQFVDMVKGK SLTGVVNAQA LTSAFSPHTK PWIGLAEALG TLMRAWAGSP KGTIQVITQG
     TSLKNAGNCL SPAVIVGLLK EASKQADVNL VNAKLLVKEA GLNVTTSHSP AAPGEQGFGE
     CLLAVALAGA PYQAVGLVQG TTPVLQGLNG AVFRPEVPLR RDLPLLLFRT QTSDPAMLPT
     MIGLLAEAGV RLLSYQTSLV SDGETWHVMG ISSLLPSLEA WKQHVTEAFQ FHF
//
